and the adjustments provided under this sub-
section— 
‘‘(i) OTC monograph drug facility fees 
under subsection (a)(1); and 
‘‘(ii) OTC monograph order request 
fees under subsection (a)(2); and 
‘‘(B) publish such fee revenue amounts, fa-
cility fees, and OTC monograph order request 
fees in the Federal Register.’’. 
(d) CREDITING AND AVAILABILITY OF FEES.—Sec-
tion 744M(f) of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 379j–72(f)) is amended— 
(1) in paragraph (2)(D)— 
(A) in the subparagraph heading, by strik-
ing ‘‘IN SUBSEQUENT YEARS’’; and 
(B) by striking ‘‘(after fiscal year 2021)’’; 
and 
(2) in paragraph (3), by striking ‘‘2021 
through 2025’’ and inserting ‘‘2026 through 2030’’. 
SEC. 505. REAUTHORIZATION; REPORTING REQUIREMENTS. 
(a) PERFORMANCE REPORT.—Section 744N of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j– 
73) is amended— 
(1) in subsection (a)— 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00058
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(A) by striking ‘‘Beginning with fiscal year 
2021, and not later than 120 calendar days 
after the end of each fiscal year thereafter’’ and 
inserting the following: 
‘‘(1) IN
GENERAL.—Not later than 120 cal-
endar days after the end of each fiscal year’’; 
(B) by striking ‘‘section 3861(b) of the 
CARES Act’’ and inserting ‘‘section 2 of the 
Over-the-Counter Monograph Drug User Fee 
Amendments’’; and 
(C) by adding at the end the following: 
‘‘(2) ADDITIONAL
INFORMATION.—Beginning 
with fiscal year 2026, the annual report under this 
subsection shall include— 
‘‘(A) the progress of the Food and Drug 
Administration in achieving the goals, and fu-
ture plans for meeting the goals, including— 
‘‘(i) the number of Tier 1 OTC mono-
graph order requests for which a proposed 
order was issued, and the number of such 
requests for which a final order was issued, 
in the previous fiscal year; 
‘‘(ii) the number of Tier 2 OTC 
monograph order requests for which a pro-
posed order was issued, and the number of 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00059
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
such requests for which a final order was 
issued, in the previous fiscal year; 
‘‘(iii) the number of specified safety 
OTC monograph order requests for which 
a proposed order was issued, and the num-
ber of such requests for which a final order 
was issued, in the previous fiscal year; 
‘‘(iv) the number of generally recog-
nized as safe and effective finalization 
OTC monograph order requests for which 
a proposed order was issued, and the num-
ber of such requests for which a final order 
was issued, in the previous fiscal year; 
‘‘(v) the average timeline for proc-
essing OTC monograph order requests, in 
the aggregate and by submission type, in 
the previous fiscal year; and 
‘‘(vi) postmarket safety activities with 
respect to OTC monograph drugs, includ-
ing— 
‘‘(I) collecting, developing, and 
reviewing safety information on OTC 
monograph drugs, including adverse 
event reports; 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00060
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(II) developing and using im-
proved analytical tools, adverse event 
data-collection systems, including in-
formation technology systems, to as-
sess potential safety problems, includ-
ing access to external databases; and 
‘‘(III) activities under section 
760; 
‘‘(B) information regarding registration of 
OTC monograph drug facilities and contract 
manufacturing organization facilities and pay-
ment of registration fees by such facilities, in-
cluding— 
‘‘(i) the OTC monograph drug facili-
ties and contract manufacturing organiza-
tion facilities that were first registered 
under section 510(c) or 510(i) in the fiscal 
year; and 
‘‘(ii) for each OTC monograph drug 
facility and contract manufacturing organi-
zation facility that was assessed a facility 
fee under section 744M(a) in the fiscal 
year, whether the facility paid such fee; 
‘‘(C) the status of implementation of evi-
dence and testing standards under section 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00061
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
505G(r) for nonprescription drugs intended for 
topical administration, including— 
‘‘(i) the application of evidence or 
testing standards; and 
‘‘(ii) the number of active ingredient 
requests for nonprescription drugs in-
tended for topical administration reviewed 
using 
the 
standards 
under 
section 
505G(b); and 
‘‘(D) the progress of the Food and Drug 
Administration in allowing nonclinical testing 
alternatives to animal testing for the consider-
ation of sunscreen active ingredients. 
‘‘(3) CONFIDENTIALITY.—Nothing in para-
graph (2) shall be construed to authorize the disclo-
sure of information that is prohibited from disclo-
sure under section 301(j) of this Act or section 1905 
of title 18, United States Code, or that is subject to 
withholding under section 552(b)(4) of title 5, 
United States Code.’’; 
(2) in subsection (b), by striking ‘‘fiscal year 
2021 and each subsequent fiscal year’’ and inserting 
‘‘each fiscal year’’; and 
(3) in subsection (d)— 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00062
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(A) by striking ‘‘2025’’ each place it ap-
pears and inserting ‘‘2030’’; and 
(B) by adding at the end the following: 
‘‘(4) MINUTES OF NEGOTIATION MEETINGS.— 
‘‘(A) PUBLIC
AVAILABILITY.—The Sec-
retary shall make publicly available, on the pub-
lic website of the Food and Drug Administra-
tion, robust written minutes of all negotiation 
meetings conducted under this subsection be-
tween the Food and Drug Administration and 
the regulated industry, not later than 30 days 
after each such negotiation meeting. 
‘‘(B) CONTENT.—The robust written min-
utes described under subparagraph (A) shall 
contain, in detail, any substantive proposal 
made by any party to the negotiations as well 
as significant controversies or differences of 
opinion during the negotiations and their reso-
lution.’’. 
(b) GAO REPORT.— 
(1) IN GENERAL.—Not later than September 
30, 2027, the Comptroller General of the United 
States shall submit to the Committee on Health, 
Education, Labor, and Pensions of the Senate and 
the Committee on Energy and Commerce of the 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00063
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
House of Representatives a report assessing the sup-
ply chain of over-the-counter monograph drugs. 
(2) CONTENTS.—The report required under 
paragraph (1) shall include an assessment of— 
(A) the overall stability of the supply chain 
of over-the-counter monograph drugs; 
(B) what information is collected by the 
Food and Drug Administration with respect to 
the supply chain of over-the-counter monograph 
drugs; 
(C) how the Food and Drug Administra-
tion uses information collected on the supply 
chain of over-the-counter monograph drugs to 
inform regulatory decisions; 
(D) how the Food and Drug Administra-
tion coordinates with other Federal agencies to 
monitor and mitigate disruptions to the supply 
chain of over-the-counter monograph drugs; and 
(E) the unique characteristics of the over- 
the-counter monograph drug marketplace and 
what additional authorities or information the 
Food and Drug Administration may need to en-
sure the stability of the supply chain of over- 
the-counter monograph drugs. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00064
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 506. TREATMENT OF ACTIVE INGREDIENTS FOR TOP-
ICAL ADMINISTRATION. 
(a) IN GENERAL.—Section 505G of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 355h) is 
amended by adding at the end the following: 
‘‘(r) EVIDENCE AND TESTING STANDARDS FOR AC-
TIVE INGREDIENTS FOR TOPICAL ADMINISTRATION.— 
‘‘(1) EVIDENCE AND TESTING STANDARDS FOR 
ACTIVE
INGREDIENTS
FOR
TOPICAL
ADMINISTRA-
TION.—The Secretary shall— 
‘‘(A) in evaluating the generally recognized 
as safe and effective status of active ingredients 
used in nonprescription drugs intended for top-
ical administration for purposes of subsection 
(a), utilize standards that allow for the use of 
real world evidence (as defined in section 
505F(b)), as appropriate, as part of a com-
prehensive evaluation of scientific evidence to 
demonstrate the safety and effectiveness of such 
active ingredients, to supplement evidence from 
traditional clinical trials, provided that such 
standards allow the Secretary to evaluate 
whether the benefits of such active ingredients 
outweigh the risks; and 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00065
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(B) apply subsection (b)(6)(C) to the reg-
ulation of active ingredients used in drugs in-
tended for topical administration. 
‘‘(2) NON-ANIMAL TESTING METHODS FOR TOP-
ICAL ACTIVE INGREDIENTS.— 
‘‘(A) IN
GENERAL.—The Secretary shall 
consider the types of nonclinical tests described 
in paragraphs (1) through (4) of the first sub-
section (z) of section 505 (as inserted by sec-
tion 3209(a)(2) of the Health Extenders, Im-
proving Access to Medicare, Medicaid, and 
CHIP, and Strengthening Public Health Act of 
2022 (division FF of Public Law 117–328)), or 
any other alternative to animal testing that the 
Secretary determines appropriate, in the consid-
eration of drugs intended for topical adminis-
tration under this section. 
‘‘(B) GUIDANCE.—Not later than 1 year 
after the date of enactment of this subsection, 
the Secretary shall issue new draft guidance on 
how sponsors can use nonclinical testing alter-
natives to animal testing, as appropriate, to 
meet safety and efficacy standards under this 
section for drugs intended for topical adminis-
tration. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00066
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(3) CLARIFICATION.—Nothing in this sub-
section shall be construed to alter, supersede, or 
limit the standards for making determinations of 
whether a drug is generally recognized as safe and 
effective under section 201(p) or the standards set 
forth under section 505 for determining the safety 
and effectiveness of drugs.’’. 
(b) SUNSCREEN FINAL ADMINISTRATIVE ORDER.— 
A final administrative order on nonprescription sunscreen 
active ingredients issued under section 3854 of the 
Coronavirus Aid, Relief, and Economic Security Act (Pub-
lic Law 116–136; 21 U.S.C. 360fff–3 note) shall— 
(1) account for historical data regarding the 
safety of sunscreen active ingredients that have pre-
viously been accepted for marketing in the United 
States; 
(2) account for the role of broad spectrum sun-
screens with a Sun Protection Factor of 15 or high-
er in effective skin cancer prevention; and 
(3) incorporate the evidence and testing stand-
ards for sunscreen active ingredients detailed in sec-
tion 505G(r) of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 355h) (as added by subsection 
(a)). 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00067
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 507. INCREASING THE CLARITY AND PREDICTABILITY 
OF THE PROCESS FOR DEVELOPING APPLI-
CATIONS 
FOR 
RX-TO-NONPRESCRIPTION 
SWITCHES. 
(a) IN GENERAL.—Section 505(b) of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) is 
amended by adding at the end the following: 
‘‘(7) RX-TO-NONPRESCRIPTION SWITCHES.— 
‘‘(A) MEETINGS.—Any person planning to 
submit an application for an Rx-to-nonprescrip-
tion switch may submit to the Secretary a writ-
ten request for a meeting, for purposes of devel-
oping a plan for such application that addresses 
the potential risks to public health of such 
switch and the evidence necessary to support 
such application, including the design of any 
necessary studies, and the format and content 
of the planned application. The Secretary may 
grant such a meeting, as appropriate, consistent 
with established procedures for granting meet-
ings with, and providing written responses to, 
applications under this section. Each such 
meeting shall be documented in meeting min-
utes. 
‘‘(B) GUIDANCE.— 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00068
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(i) IN GENERAL.—Not later than 18 
months after the date of enactment of this 
paragraph, the Secretary shall issue guid-
ance to increase the clarity and predict-
ability of the process and standards for ap-
proval of applications for nonprescription 
drugs under this section, including in the 
case of applications for an Rx-to-non-
prescription switch, especially with respect 
to prescription drugs with well-established 
safety profiles for which an applicant may 
seek approval for nonprescription use. 
‘‘(ii) 
CONTENTS.—The 
guidance 
under clause (i) shall— 
‘‘(I) describe how published re-
ports in medical literature, any pre-
vious finding of safety or effectiveness 
for the drug under this section, the 
results of significant human experi-
ence with the drug, unpublished stud-
ies and other data, and other sources 
of information may be used to support 
an application for a nonprescription 
drug, including in the context of an 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00069
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
application for an Rx-to-nonprescrip-
tion switch; 
‘‘(II) set forth procedures for 
sponsors to request meetings de-
scribed in subparagraph (A) and doc-
ument the recommendations made in 
such meetings; 
‘‘(III) describe evidentiary expec-
tations to support approval of an ap-
plication for a nonprescription drug, 
including in the context of an applica-
tion 
for 
an 
Rx-to-nonprescription 
switch, including how sponsors can 
demonstrate that consumers can ap-
propriately self-select and use the 
drug 
and 
comprehend 
the 
non-
prescription drug label; and 
‘‘(IV) provide recommendations 
for how mechanisms, in addition to 
the required Drug Facts Label, such 
as mobile applications and decisions 
aids, can be incorporated into the in-
formation submitted in support of an 
application for an Rx-to-nonprescrip-
tion switch. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00070
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(C) PLAN
TO
ENGAGE
WITH
STAKE-
HOLDERS.—Not later than 1 year after the 
date of enactment of this paragraph, the Sec-
retary shall develop and make publicly available 
on the website of the Food and Drug Adminis-
tration a plan to engage stakeholders on steps 
and factors for application holders and other 
stakeholders to consider in identifying approved 
prescription drugs that may be promising can-
didates for applications for an Rx-to-non-
prescription switch. 
‘‘(D) DEFINITION.—For purposes of this 
paragraph, the term ‘Rx-to-nonprescription 
switch’ means the approval of an application, or 
supplemental application, as applicable, sub-
mitted under this section by the holder of an 
approved application for a prescription drug 
seeking approval to market such drug as a non-
prescription drug, including for— 
‘‘(i) 
a 
full 
Rx-to-nonprescription 
switch, under which a drug previously ap-
proved for prescription use only is— 
‘‘(I) approved for nonprescription 
use under the same conditions as ap-
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00071
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
plied to the drug when approved for 
prescription use; or 
‘‘(II) approved for nonprescrip-
tion use subject to one or more addi-
tional conditions for nonprescription 
use; and 
‘‘(ii) a partial Rx-to-nonprescription 
switch, under which the drug is approved 
for nonprescription use only under certain 
conditions described in the approved label-
ing, while the drug otherwise remains ap-
proved for prescription use only. 
‘‘(E) RULE OF CONSTRUCTION.—Nothing 
in this paragraph shall be construed to— 
‘‘(i) supersede or modify the authority 
of the Secretary under section 505G with 
respect to the regulation of OTC mono-
graph drugs; or 
‘‘(ii) authorize the disclosure by the 
Secretary of confidential commercial infor-
mation or trade secrets.’’. 
(b) GAO REPORT.— 
(1) IN GENERAL.—Not later than 1 year after 
the date of enactment of this Act, the Comptroller 
General of the United States shall submit to the 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00072
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
Committee on Health, Education, Labor, and Pen-
sions of the Senate and the Committee on Energy 
and Commerce of the House of Representatives a re-
port that evaluates— 
(A) the number of applications for an Rx- 
to-nonprescription switch approved during the 
period beginning on October 1, 2022, and end-
ing on the date of the report; 
(B) the number of drugs for which an ap-
plication for an Rx-to-nonprescription switch 
was approved during such period subject to an 
additional condition for nonprescription use; 
(C) among the drugs for which an applica-
tion for a full or partial Rx-to-nonprescription 
switch was approved during such period, the av-
erage length of time from receipt by the Food 
and Drug Administration of the application to 
the approval of such application; 
(D) the number of partial Rx-to-non-
prescription switch applications approved dur-
ing such period, and the number of applications 
for such a partial switch not approved; 
(E) any barriers to timely and predictable 
review of applications for an Rx-to-nonprescrip-
tion switch; 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00073
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(F) engagement by the Food and Drug 
Administration with public stakeholders, includ-
ing public meetings or additional activities to 
support review of applications for an Rx-to-non-
prescription switch; and 
(G) opportunities for collaboration between 
the Center for Drug Evaluation and Research 
and the Centers for Medicare & Medicaid Serv-
ices for the purpose of analyzing health insur-
ance claims data for commonly prescribed drugs 
that appear to be suitable for an Rx-to-non-
prescription switch. 
(2) DEFINITION.—In this subsection, the term 
‘‘Rx-to-nonprescription switch’’ has the meaning 
given such term in paragraph (7) of section 505(b) 
of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 244(b)), as added by subsection (a). 
SEC. 508. REGULATION OF CERTAIN NONPRESCRIPTION 
DRUGS THAT ARE MARKETED WITHOUT AN 
APPROVED DRUG APPLICATION. 
(a) DEVELOPMENT ADVICE TO SPONSORS OR RE-
QUESTORS.—Section 505G(h) of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 355h(h)) is amended by 
striking ‘‘sponsors or requestors’’ and inserting ‘‘sponsors, 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00074
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
requestors, or organizations nominated by sponsors or re-
questors to represent their interests in a proceeding’’. 
(b) 
TECHNICAL
CORRECTION.—Section 
505G(b)(2)(A)(iv)(III) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355h(b)(2)(A)(iv)(III)) is 
amended by striking ‘‘requestors’’ and inserting ‘‘sponsors 
or requestors’’. 
SEC. 509. SUNSET DATES. 
(a) AUTHORIZATION.—Sections 744L and 744M of 
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
379j–71; 379j–72) shall cease to be effective October 1, 
2030. 
(b) REPORTING REQUIREMENTS.—Section 744N of 
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
379j–73) shall cease to be effective January 31, 2031. 
SEC. 510. EFFECTIVE DATE. 
The amendments made by this title shall take effect 
on October 1, 2025, or the date of the enactment of this 
Act, whichever is later, except that fees under part 10 of 
subchapter C of chapter VII of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 379j–71 et seq.) shall be 
assessed beginning October 1, 2025, regardless of the date 
of the enactment of this Act. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00075
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 511. SAVINGS CLAUSE. 
Notwithstanding the amendments made by this title, 
part 10 of subchapter C of chapter VII of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 379j–71 et 
seq.), as in effect on the day before the date of enactment 
of this Act, shall continue to be in effect with respect to 
assessing and collecting any fee required by such part for 
a fiscal year prior to fiscal year 2026. 
TITLE VI—NO SURPRISES ACT 
IMPLEMENTATION 
SEC. 601. EXTENDING AVAILABILITY OF FUNDING FOR NO 
SURPRISES ACT IMPLEMENTATION. 
Section 118(a) of division BB of the Consolidated 
Appropriations Act, 2021 (Public Law 116–260) is 
amended— 
(1) by striking ‘‘otherwise appropriated, to the 
Secretary of Health and Human Services’’ and in-
serting the following: ‘‘otherwise appropriated— 
‘‘(1) to the Secretary of Health and Human 
Services’’; 
(2) in paragraph (1), as so inserted, by striking 
‘‘September 30, 2025.’’ and inserting ‘‘November 
21, 2025; and’’; and 
(3) by adding at the end the following new 
paragraph: 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00076
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(2) to the Secretary of Health and Human 
Services, in addition to amounts otherwise appro-
priated under paragraph (1), $15,000,000 for the 
period beginning on October 1, 2025, and ending on 
November 21, 2025.’’. 
DIVISION D—DEPARTMENT OF 
VETERANS AFFAIRS EXTENDERS 
TITLE I—HEALTH CARE 
MATTERS 
SEC. 101. EXTENSION OF AUTHORITY FOR COLLECTION OF 
COPAYMENTS 
FOR 
HOSPITAL 
CARE 
AND 
NURSING HOME CARE. 
Section 1710(f)(2)(B) of title 38, United States 
Code, is amended by striking ‘‘September 30, 2025’’ and 
inserting ‘‘November 21, 2025’’. 
SEC. 102. EXTENSION OF REQUIREMENT TO PROVIDE 
NURSING HOME CARE TO CERTAIN VET-
ERANS WITH SERVICE-CONNECTED DISABIL-
ITIES. 
Section 1710A(d) of title 38, United States Code, is 
amended by striking ‘‘September 30, 2025’’ and inserting 
‘‘November 21, 2025’’. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00077
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 103. EXTENSION OF STAFF SERGEANT PARKER GOR-
DON FOX SUICIDE PREVENTION GRANT PRO-
GRAM. 
Section 201(j) of the Commander John Scott 
Hannon Veterans Mental Health Care Improvement Act 
of 2019 (Public Law 116–171; 38 U.S.C. 1720F note) 
is amended by striking ‘‘the date that is three years after 
the date on which the first grant is awarded under this 
section’’ and inserting ‘‘November 21, 2025’’. 
SEC. 104. EXTENSION OF FUNDING FOR EXPANSION OF 
RURAL ACCESS NETWORK FOR GROWTH EN-
HANCEMENT PROGRAM. 
Section 2(d) of the Sgt. Ketchum Rural Veterans 
Mental Health Act of 2021 (Public Law 117–21; 38 
U.S.C. 1712A note) is amended by striking ‘‘2025’’ and 
inserting ‘‘2026’’. 
TITLE II—BENEFITS 
SEC. 201. EXTENSION OF REQUIREMENT FOR QUARTERLY 
BRIEFINGS 
ON 
ADMINISTRATION 
OF 
AU-
THORITIES RELATING TO DETERMINATIONS 
REGARDING 
PRESUMPTIONS 
OF 
SERVICE 
CONNECTION BASED ON TOXIC EXPOSURE. 
Section 202(b)(2) of the Sergeant First Class Heath 
Robinson Honoring our Promise to Address Comprehen-
sive Toxics Act of 2022 (Public Law 117–168) is amended 
by striking ‘‘On a quarterly basis during the two-year pe-
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00078
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
riod beginning on the date of the enactment of this Act,’’ 
and inserting ‘‘On a quarterly basis during the period be-
ginning on the date of the enactment of this Act and end-
ing on December 31, 2026,’’. 
SEC. 202. EXTENSION OF REQUIREMENT RELATING TO RES-
TORATION 
OF 
ENTITLEMENT 
TO 
EDU-
CATIONAL ASSISTANCE IN CASES OF CLO-
SURE OR DISAPPROVAL OF EDUCATIONAL IN-
STITUTIONS. 
Section 3699(c)(2)(C) of title 38, United States 
Code, is amended by striking ‘‘September 30, 2025’’ and 
inserting ‘‘November 21, 2025’’. 
SEC. 203. EXTENSION OF TEMPORARY CLARIFICATION OF 
LICENSURE 
REQUIREMENTS 
FOR 
CON-
TRACTOR MEDICAL PROFESSIONALS TO PER-
FORM MEDICAL DISABILITY EXAMINATIONS 
FOR THE DEPARTMENT OF VETERANS AF-
FAIRS UNDER PILOT PROGRAM FOR USE OF 
CONTRACT PHYSICIANS FOR DISABILITY EX-
AMINATIONS. 
Section 2002(a)(4) of the Johnny Isakson and David 
P. Roe, M.D. Veterans Health Care and Benefits Improve-
ment Act of 2020 (Public Law 116–315; 38 U.S.C. 5101 
note) is amended by striking ‘‘five years’’ and inserting 
‘‘six years’’. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00079
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 204. EXTENSION OF AUTHORITY TO MAINTAIN RE-
GIONAL 
OFFICE 
IN 
REPUBLIC 
OF 
PHIL-
IPPINES. 
Section 315(b) of title 38, United States Code, is 
amended by striking ‘‘September 30, 2025’’ and inserting 
‘‘November 21, 2025’’. 
TITLE III—HOUSING 
SEC. 301. EXTENSION OF AUTHORIZATION OF APPROPRIA-
TIONS FOR HOMELESS WOMEN VETERANS 
AND HOMELESS VETERANS WITH CHILDREN 
REINTEGRATION GRANT PROGRAM. 
Section 2021A(f)(1) of title 38, United States Code, 
is amended by striking ‘‘2025’’ and inserting ‘‘2026’’. 
SEC. 302. EXTENSION OF AUTHORITY FOR TREATMENT AND 
REHABILITATION FOR SERIOUSLY MENTALLY 
ILL AND HOMELESS VETERANS. 
(a) GENERAL TREATMENT.—Section 2031(b) of title 
38, United States Code, is amended by striking ‘‘Sep-
tember 30, 2025’’ and inserting ‘‘November 21, 2025’’. 
(b) ADDITIONAL
SERVICES
AT
CERTAIN
LOCA-
TIONS.—Section 2033(d) of title 38, United States Code, 
is amended by striking ‘‘September 30, 2025’’ and insert-
ing ‘‘November 21, 2025’’. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00080
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 303. EXTENSION OF FUNDING FOR FINANCIAL ASSIST-
ANCE FOR SUPPORTIVE SERVICES FOR VERY 
LOW-INCOME VETERAN FAMILIES IN PERMA-
NENT HOUSING. 
Of the amounts appropriated to the Department of 
Veterans Affairs for fiscal year 2026 for ‘‘Medical Serv-
ices’’, $92,000,000 shall be available until November 21, 
2025, to carry out subsections (a), (b), and (c) of section 
2044 of title 38, United States Code. 
SEC. 304. EXTENSION OF FUNDING FOR GRANT PROGRAM 
FOR HOMELESS VETERANS WITH SPECIAL 
NEEDS. 
Of the amounts appropriated to the Department of 
Veterans Affairs for fiscal year 2026 for ‘‘Medical Serv-
ices’’, $833,333 shall be available until November 21, 
2025, for the purposes of the program under section 2061 
of title 38, United States Code. 
SEC. 305. EXTENSION OF AUTHORITY TO PROVIDE ASSIST-
ANCE FOR SPECIALLY ADAPTED HOUSING 
FOR DISABLED VETERANS RESIDING TEMPO-
RARILY IN HOUSING OWNED BY A FAMILY 
MEMBER. 
Section 2102A(e) of title 38, United States Code, is 
amended by striking ‘‘September 30, 2025’’ and inserting 
‘‘November 21, 2025’’. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00081
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 306. EXTENSION OF AUTHORITY FOR SPECIALLY 
ADAPTED HOUSING ASSISTIVE TECHNOLOGY 
GRANT PROGRAM. 
Section 2108(g) of title 38, United States Code, is 
amended by striking ‘‘September 30, 2025’’ and inserting 
‘‘November 21, 2025’’. 
SEC. 307. IMPROVEMENTS TO PARTIAL CLAIM PROGRAM 
OF THE DEPARTMENT OF VETERANS AF-
FAIRS. 
(a) CLARIFICATION OF RELATIONSHIP TO OTHER 
POWERS OF SECRETARY.—Section 3720(h) of title 38, 
United States Code, is amended by striking ‘‘of subsection 
(a)’’ and all that follows through the period at the end 
and inserting ‘‘of subsection (a) in conjunction with the 
purchase of a loan under section 3732(a)(2) of this title 
unless the Secretary determines the purchase would be 
made consistent with section 3732(d) of this title.’’. 
(b) ADMINISTRATION
OF
PARTIAL
CLAIM
PRO-
GRAM.—Section 3737 of such title is amended— 
(1) in subsection (b)(2), by striking ‘‘first lien 
guaranteed loan for such property’’ and inserting 
‘‘amount of indebtedness under the guaranteed loan 
that the Secretary does not purchase’’; and 
(2) in subsection (c)— 
(A) in paragraph (2)(B)(ii), by striking 
‘‘120 days’’ and inserting ‘‘180 days’’; and 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00082
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(B) by amending paragraph (3) to read as 
follows: 
‘‘(3) An amount paid to the holder of a loan as a 
partial claim— 
‘‘(A) shall not alter the guaranty calculation 
specified by section 3703 of this title; 
‘‘(B) shall be included, for the purpose of a liq-
uidation sale, in the same manner as any other ad-
vance allowed by the Secretary; and 
‘‘(C) shall not be claimed under the guaranty or 
increase the Secretary’s cost of acquisition of the 
property securing the defaulted loan.’’. 
(c) REQUIREMENTS
OF LOAN HOLDER.—Section 
(d)(1) of such section is amending by inserting ‘‘and serv-
icing the loan’’ after ‘‘documents’’. 
(d) DEFAULT AND FORECLOSURE.—Subsection (e) 
of such section is amended— 
(1) in paragraph (1)— 
(A) in subparagraph (A), by striking ‘‘an 
individual who’’ and all that follows through the 
period at the end and inserting the following: 
‘‘a borrower who defaults on a partial claim 
shall be liable to the Secretary for any loss suf-
fered by the Secretary with respect to such de-
fault, and such loss may be recovered in the 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00083
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
same manner as any other debt due the United 
States. The Secretary shall not restore housing 
loan entitlement under section 3702(b) of this 
title until such loss is repaid in full.’’; and 
(B) by amending subparagraph (B) to read 
as follows: 
‘‘(B) The Secretary may charge administrative costs, 
fees, and interest, as appropriate, with respect to any de-
fault under a partial claim in a manner similar to the in-
terest and administrative costs charged under section 
5315 of this title.’’; and 
(2) by amending paragraph (2) to read as fol-
lows: 
‘‘(2) Notwithstanding section 2410 of title 28, a non-
judicial sale of real property to satisfy a loan guaranteed 
under this chapter shall discharge the property from a 
partial claim interest held by the Secretary, provided that 
the holder of the guaranteed loan conducts the non-judi-
cial sale and distributes the sale proceeds, if any, in ac-
cordance with the State or local law where such property 
is situated.’’. 
(e) GUIDANCE IN ADVANCE OF REGULATIONS.—Sub-
section (h) of such section is amended to read as follows: 
‘‘(h) GUIDANCE IN ADVANCE OF REGULATIONS.— 
Notwithstanding any other provision of law, the Secretary 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00084
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
may, before prescribing regulations, issue administrative 
guidance with respect to the Partial Claim Program under 
this section and the loss mitigation options prescribed 
under section 3732(d) of this title, including any addi-
tional terms, conditions, and requirements the Secretary 
determines necessary.’’. 
SEC. 308. GOVERNMENT ACCOUNTABILITY OFFICE RE-
PORTS ON PARTIAL CLAIM PROGRAM OF THE 
DEPARTMENT OF VETERANS AFFAIRS AND 
OTHER MATTERS. 
(a) ANNUAL REPORTS.— 
(1) IN
GENERAL.—Not later than one year 
after the date of the enactment of this Act, and 
every year thereafter until the Partial Claim Pro-
gram terminates, the Comptroller General of the 
United States shall submit to the Committee on Vet-
erans’ Affairs of the Senate and the Committee on 
Veterans’ Affairs of the House of Representatives a 
report. 
(2) ELEMENTS.—Each report required by para-
graph (1) shall include, for the period covered by the 
report and disaggregated by quarter, the following: 
(A) Key data on the performance of the 
Partial Claim Program, including— 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00085
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(i) the number of partial claims filed 
and approved; and 
(ii) the redefault and foreclosure rates 
of loans for which a partial claim was 
made. 
(B) A comparison of the data described in 
subparagraph (A) with data on the performance 
of other loss mitigation options provided by the 
Department of Veterans Affairs. 
(C) The number of housing loans insured, 
guaranteed, or made by the Secretary of Vet-
erans Affairs under chapter 37 of title 38, 
United States Code. 
(D) The number of applications for hous-
ing loan benefits under such chapter denied. 
(E) The number of housing loans insured, 
guaranteed, or made by the Secretary under 
such 
chapter 
refinanced 
under 
section 
3710(a)(8) or 3712 of title 38, United States 
Code. 
(F) The number of veterans who owe a 
payment on a mortgage associated with a loan 
insured, guaranteed, or made by the Secretary 
under such chapter that is at least— 
(i) 60 days late; and 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00086
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(ii) 90 days late. 
(b) ASSESSMENT.— 
(1) IN GENERAL.—Not later than one year be-
fore the Partial Claim Program terminates, the 
Comptroller General shall— 
(A) conduct an assessment of the benefits 
and challenges of the Partial Claim Program; 
and 
(B) submit to the Committee on Veterans’ 
Affairs of the Senate and the Committee on 
Veterans’ Affairs of the House of Representa-
tives a report on the findings of the Comptroller 
General with respect to that assessment. 
(2) CONSIDERATIONS.—In conducting the as-
sessment required by paragraph (1), the Comptroller 
General shall consider the following: 
(A) The characteristics of borrowers for 
whom a partial claim was made compared to 
the characteristics of borrowers provided other 
loss mitigation options by the Department of 
Veterans Affairs. 
(B) The performance of loans guaranteed 
under chapter 37 of title 38, United States 
Code, following various loss mitigation actions. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00087
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(C) The information the Department con-
sidered in determining whether a borrower 
would benefit from a partial claim compared to 
other loss mitigation options. 
(D) The costs to taxpayers of the Partial 
Claim Program compared to the costs of other 
loss mitigation options provided by the Depart-
ment. 
(E) Any similarities and differences in the 
Department’s administration and use of the 
Partial Claim Program compared to the De-
partment’s administration and use of the 
COVID–19 Veterans Assistance Partial Claim 
Payment program established under subpart F 
of part 36 of title 38, Code of Regulations. 
(F) The information the Department 
learned from the COVID–19 Veterans Assist-
ance Partial Claim Payment program and the 
extent to which those lessons learned were ap-
plied to the Partial Claim Program. 
(G) The types of information the Depart-
ment collected to monitor the performance and 
effectiveness of the Partial Claim Program and 
how the Department used that information to 
make any needed adjustments to the program. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00088
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(H) How the use by the Department of 
partial claims compares to the use of partial 
claims by other Federal housing agencies, in-
cluding, for each partial claim program— 
(i) the volume of loans for which par-
tial claims have been made; 
(ii) the results for borrowers (includ-
ing redefault and foreclosure rates); and 
(iii) the costs to taxpayers. 
(c) PARTIAL CLAIM PROGRAM DEFINED.—In this 
section, the term ‘‘Partial Claim Program’’ means the 
Partial Claim Program of the Department of Veterans Af-
fairs carried out under section 3737 of title 38, United 
States Code. 
TITLE IV—OTHER MATTERS 
SEC. 401. EXTENSION OF SUBPOENA AUTHORITY OF IN-
SPECTOR GENERAL OF DEPARTMENT OF 
VETERANS AFFAIRS. 
Section 312(d)(7)(A) of title 38, United States Code, 
is amended by striking ‘‘September 30, 2025’’ and insert-
ing ‘‘November 21, 2025’’. 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00089
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
SEC. 402. EXTENSION OF AUTHORITY FOR SECRETARY OF 
VETERANS AFFAIRS TO TRANSPORT INDIVID-
UALS TO AND FROM FACILITIES OF DEPART-
MENT OF VETERANS AFFAIRS. 
Section 111A(a)(2) of title 38, United States Code, 
is amended by striking ‘‘September 30, 2025’’ and insert-
ing ‘‘November 21, 2025’’. 
SEC. 403. EXTENSION OF AUTHORITY RELATING TO VEND-
EE LOAN PROGRAM. 
Section 3733(a)(8) of title 38, United States Code, 
is amended— 
(1) in the matter preceding subparagraph (A), 
by striking ‘‘September 30, 2025’’ and inserting 
‘‘November 21, 2025’’; and 
(2) in subparagraph (C), by striking ‘‘Sep-
tember 30, 2025’’ and inserting ‘‘November 21, 
2025’’. 
SEC. 404. EXTENSION OF AUTHORITY FOR TRANSFER OF 
REAL PROPERTY. 
Section 8118(a)(5) of title 38, United States Code, 
is amended by striking ‘‘September 30, 2025’’ and insert-
ing ‘‘November 21, 2025’’. 
DIVISION E—MISCELLANEOUS 
SEC. 101. BUDGETARY EFFECTS. 
(a) STATUTORY PAYGO SCORECARDS.—The budg-
etary effects of divisions B through D shall not be entered 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00090
Fmt 6652
Sfmt 6201
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB
on either PAYGO scorecard maintained pursuant to sec-
tion 4(d) of the Statutory Pay-As-You-Go Act of 2010. 
(b) SENATE PAYGO SCORECARDS.—The budgetary 
effects of divisions B through D shall not be entered on 
any PAYGO scorecard maintained for purposes of section 
4106 of H. Con. Res. 71 (115th Congress). 
(c) CLASSIFICATION
OF BUDGETARY EFFECTS.— 
Notwithstanding Rule 3 of the Budget Scorekeeping 
Guidelines set forth in the joint explanatory statement of 
the committee of conference accompanying Conference Re-
port 105–217 and section 250(c)(8) of the Balanced 
Budget and Emergency Deficit Control Act of 1985, the 
budgetary effects of divisions B through D shall not be 
estimated— 
(1) for purposes of section 251 of such Act; 
(2) for purposes of an allocation to the Com-
mittee on Appropriations pursuant to section 302(a) 
of the Congressional Budget Act of 1974; and 
(3) for purposes of paragraph (4)(C) of section 
3 of the Statutory Pay-As-You-Go Act of 2010 as 
being included in an appropriation Act. 
Æ 
VerDate Sep 11 2014 
00:15 Sep 17, 2025
Jkt 059200
PO 00000
Frm 00091
Fmt 6652
Sfmt 6301
E:\BILLS\H5371.IH
H5371
kjohnson on DSK7ZCZBW3PROD with $$_JOB